S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

This study is currently recruiting participants.
Verified November 2013 by Southwest Oncology Group
Sponsor:
Collaborators:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT01668719
First received: August 16, 2012
Last updated: November 11, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)